Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Form 8-K

sec.gov
SSII The article is a Form 8-K filing announcing the appointment of a new CFO, Sarah M. Romano. It details her employment agreement and previous experience. The filing itself is a routine corporate disclosure and does not inherently provide positive or negative sentiment about the company's stock performance. RBOT The article mentions Vicarious Surgical Inc. (RBOT) as the previous employer of the newly appointed CFO, Sarah M. Romano. This is a factual mention and does not convey any specific sentiment about Vicarious Surgical Inc.'s current performance or prospects. KPRX The article mentions Kiora Pharmaceuticals, Inc. (KPRX) as a former employer of the new CFO. This is a factual reference and does not provide any sentiment regarding Kiora Pharmaceuticals Inc.'s current business or stock.

8-K — SS Innovations International, Inc.

Accession: 0001213900-26-077784

Filed: 2026-07-14

Period: 2026-07-14

CIK: 0001676163

SIC: 3841 (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS)

Item: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Item: Financial Statements and Exhibits

Documents

8-K — ea0297601-8k_ssinnova.htm (Primary)

EX-10.1 — EMPLOYMENT AGREEMENT BETWEEN SS INNOVATIONS INTERNATIONAL, INC. AND SARAH M. ROMANO (ea029760101ex10-1.htm)

EX-99.1 — PRESS RELEASE, DATED JULY 14, 2026 (ea029760101ex99-1.htm)

GRAPHIC (ea029760101_ex99-1img1.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — CURRENT REPORT

8-K (Primary)

Filename: ea0297601-8k_ssinnova.htm · Sequence: 1

false

0001676163

0001676163

2026-07-14

2026-07-14

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

Pursuant to Section 13 or 15(d) of The Securities

Exchange Act of 1934

Date of report (Date of earliest event reported):

July 14, 2026

SS INNOVATIONS INTERNATIONAL, INC.

(Exact name of registrant as specified in its charter)

Florida

001-42615

47-3478854

(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

405, 3rd Floor, iLabs Info Technology Centre

Udyog Vihar, Phase III

Gurugram,

Haryana India

122016

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s telephone number, including

area code: +91 73375 53469

(Former name or former address, if changed since

last report)

Check the appropriate box below if the Form 8-K

filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General

Instruction A.2. below):

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b)

of the Act:

Title

of each Class

Trading

Symbol

Name

of each exchange on which registered

Common Stock

SSII

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant

is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the

Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check

mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting

standards provided pursuant to Section 13(a) of the Exchange Act. ☐

As used in this Current Report on Form 8-K (this “Current

Report”), the terms “SSi,” “the Company,” “we,” “us”

and “our” refer to SS Innovations International, Inc. and its subsidiaries.

Item 5.02 Departure of Directors or Certain

Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Appointment of new Chief

Financial Officer

On July 14, 2026, we issued a press release announcing

the appointment of Sarah M. Romano as the Company’s new Chief Financial Officer, effective August 3, 2026. Ms. Romano will be based

in the United States. A copy of the press release is attached as Exhibit 99.1 to this Current Report and is incorporated

herein by reference.

Ms. Romano, 46, has over two decades of experience

as a financial professional. Prior to joining the Company, from April 2025 to July 2026, Ms. Romano served as the Chief Financial

Officer and Treasurer of Vicarious Surgical Inc. (NYSE/OTCQB: RBOT), a robotic surgery company developing next-generation minimally invasive

surgical technology. She previously served as Chief Financial Officer of Entero Therapeutics, Inc. (Nasdaq: ENTO) (formerly First Wave

BioPharma), a clinical-stage biopharmaceutical company specializing in the development of targeted, orally delivered therapies for gastrointestinal

diseases, from March 2022 to March 2025. Prior thereto, she served as Chief Financial Officer of Kiora Pharmaceuticals, Inc. (Nasdaq:

KPRX) (formerly EyeGate Pharmaceuticals, Inc.), a clinical-stage specialty pharmaceutical company developing products for treating ophthalmic

diseases, from February 2017 through February 2022, and as its Corporate Controller from August 2016 to January 2017. Ms. Romano began

her career as an auditor in the Boston office of PricewaterhouseCoopers. A licensed CPA in Massachusetts, she holds a Bachelor of Arts

in Accounting from College of the Holy Cross and a Master of Accounting from Boston College.

The Company and Ms. Romano entered into a three-year

employment agreement, effective August 3, 2026 (the “Employment Agreement”), providing for annual base compensation

of $440,000. Ms. Romano will be eligible for an annual cash bonus based on achievement of certain performance criteria and subject to

the terms of the Employment Agreement. In addition, the Employment Agreement provides for Ms. Romano to receive a grant of options under

the Company’s 2026 Incentive Stock Plan (the “Incentive Plan”) to purchase 750,000 shares of the Company’s

common stock vesting as to 250,000 shares on the first anniversary of the effective date and thereafter in twenty-three (23) installments

of 20,833 shares, and a final monthly installment of 20,841 shares, subject to continued employment of Ms. Romano by the Company and the

other terms and conditions of the Incentive Plan. The Employment Agreement also contains customary confidentiality, assignment of proprietary

rights, non-competition and non-solicitation provisions.

In addition to the foregoing, on the effective date of the Employment

Agreement the Company will enter into an indemnification agreement with Ms. Romano in the form of Exhibit A to the Employment Agreement.

The above summary of the Employment Agreement

is qualified in its entirety by reference to the Employment Agreement, a copy of which is attached as Exhibit 10.1 to this Current

Report and is incorporated herein by reference.

1

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.

Description

10.1

Employment Agreement between SS Innovations International, Inc. and Sarah M. Romano

99.1

Press Release, dated July 14, 2026

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

2

SIGNATURES

Pursuant to the requirements of the Securities

Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: July 14, 2026

SS INNOVATIONS INTERNATIONAL, INC.

By:

/s/ Sudhir Srivastava

Sudhir Srivastava, M.D.

Chairman and Chief Executive Officer

3

EX-10.1 — EMPLOYMENT AGREEMENT BETWEEN SS INNOVATIONS INTERNATIONAL, INC. AND SARAH M. ROMANO

EX-10.1

Filename: ea029760101ex10-1.htm · Sequence: 2

Exhibit

10.1

EXECUTIVE

EMPLOYMENT AGREEMENT

This

EXECUTIVE EMPLOYMENT AGREEMENT (the “Agreement”) is made and entered into as of June 22, 2026, by and between

SS INNOVATIONS INTERNATIONAL, INC., a Florida corporation, (the “Company”) and SARAH M. ROMANO, an individual

“Executive”).

RECITALS

WHEREAS,

the Company desires to secure the services of Executive, and the Executive desires to furnish such services to the Company, on and subject

to, the terms and conditions set forth in this Agreement; and

WHEREAS,

Executive, due to the nature of Executive’s duties, will be provided access to the Company’s trade secrets and other confidential

information and the Company desires to maintain the confidentiality of the same.

AGREEMENT

NOW,

THEREFORE, in consideration of the mutual covenants and agreements herein contained and other good and valuable consideration, the

receipt and sufficiency of which is hereby acknowledged, the parties agree as follows:

1.

Recitals. The above recitals are true and correct and are incorporated herein by reference.

2.

Position and Duties. Executive shall serve as Chief Financial Officer (“CFO”) of the Company, reporting

to the Company’s Chief Executive Officer (“CEO”) and board of directors (the “Board”). Executive

shall perform those services customary to the office of CFO and such other lawful duties that may be reasonably assigned to her from

time to time by the CEO and/or the Board, provided those duties are consistent with Executive’s position and authority. Executive further

agrees to use her best efforts to promote the interests of the Company and to devote her full business time and energies to the business

and affairs of the Company, provided, however, that the foregoing shall not be construed to prohibit Executive from engaging in

activities relating to serving on corporate, civic, charitable, or not-for-profit boards or committees, or from managing her personal

passive investments, provided that such activities do not materially interfere or conflict with the performance by Executive of Executive’s

duties and responsibilities hereunder. Executive may continue her existing board service and may serve on other boards of directors,

including public company boards, provided that such service does not create a conflict of interest with the Company and does not materially

interfere with the performance of Executive’s duties. Executive shall provide prior notice to the Board before accepting any future

public company directorship. At all times, Executive shall perform and discharge faithfully, diligently, and in a professional manner,

Executive’s duties and responsibilities hereunder.

Page 1 of 23

3.

Term. The Company shall continue to employ Executive and Executive shall continue to serve the Company, on and subject

to, the terms and conditions set forth herein, for the period commencing on August 3, 2026 (the “Effective Date”),

and expiring on August 3, 2029, unless this Agreement is sooner terminated as set forth herein (the “Initial Term”).

This Agreement shall automatically renew for successive one (1) year periods (each, a “Renewal Term,” and together

with the Initial Term, the “Term”), unless either party gives notice of non-renewal of this Agreement at least sixty

(60) days prior to expiration of the Initial Term or any Renewal Term, or unless this Agreement is sooner terminated as hereinafter set

forth.

4.

Place of Employment. The Company and Executive agree that Executive will predominantly perform her duties remotely from

her principal residence, with travel to the Company’s headquarters in Gurugram, Haryana, India, such other business locations established

by the Company within the United States, or such other locations, all as reasonably requested by the Company or required by her position.

5.  Compensation

and Related Matters.

(a)

Base Salary. Executive’s annual base salary shall be four hundred forty thousand dollars ($440,000) (together with any

subsequent increases thereto as hereinafter provided, the “Base Salary”). The Base Salary may be increased by the

Board or its compensation committee (the “Committee”) from time to time during the Term but shall be reviewed at least

once annually. The Base Salary shall be paid in accordance with the Company’s normal payroll practices, in effect from time to

time during the Term.

(b)  Annual

Bonus. During the Term, Executive shall be eligible for an annual cash bonus with a target amount of 40% of Base Salary,

based on achievement of performance criteria agreed upon between Executive and the Committee or the Board within the first ninety

(90) days after the Effective Date, with respect to the period commencing on the Effective Date and ending on December 31, 2026 (the

“Initial Period”), and within ninety (90) days of the beginning of each subsequent fiscal year during the Term.

The bonus shall be paid no later than March 31 of the year following the Initial Period or the fiscal year in which it is earned.

Any changes to the bonus criteria during the Initial Period or each subsequent fiscal year during the Term shall require Executive’s

written consent. In order to be eligible to receive the annual cash bonus, Executive must be employed by the Company on the date

that annual cash bonuses are paid to senior management generally.

(c)  Equity

Incentives.

(i)

On the Effective Date, the Company shall grant to Executive options to purchase 750,000 shares of common stock (the

“Options”) under the Company’s 2026 Incentive Stock Plan (the “2026 Plan”). The Options

will (A) vest as to 250,000 shares on the first anniversary of the Effective Date and thereafter in twenty-three (23) monthly

installments of 20,833 shares, and a final monthly installment of 20,841 shares , subject to continued employment of Executive by

the Company; (B) be exercisable at a price per share equal to fair market value (as defined in the 2026 Plan); (C) expire five (5)

years from the Effective Date; and (D) be subject to the other terms and conditions of the 2026 Plan. Notwithstanding the foregoing,

in the event a Change in Control (as defined in Section 8) occurs prior to the vesting of the Options in full and Executive

is still in the employment of the Company at such time, any unvested portion of the Options shall immediately vest in

full.

(ii)

In addition to the foregoing, during the Term, Executive shall be eligible to participate in the 2026 Plan and any successor equity incentive

plan, subject to such terms and conditions as determined by the Committee or the Board in their sole discretion.

Page 2 of 23

(d)

Business Expenses. Executive shall be entitled to receive prompt reimbursement reasonable and customary business expenses

incurred by her in performing services hereunder, in accordance with the policies and procedures then in effect and established by the

Company for its senior executives. Notwithstanding the foregoing, Executive acknowledges and agrees that airfare for flights of less

than four (4) hours duration or less shall be in premium economy class (or economy class if not available) and airfare for flights of

four (4) hours duration or more shall be in business or domestic first class.

(e)

Health Insurance. Executive shall be reimbursed during the Term for the premiums for a gold standard health plan (including

medical, dental and vision coverage) covering Executive and her dependents approved by the Board in its reasonable discretion. Executive

shall submit such reasonable documentation of the amount and payment of such premiums. At such time as the Company establishes a health

insurance plan for its U.S. – based executives and employees, Executive shall participate in such plan on the same basis as offered

to other members of senior management.

(f)

Directors’ and Officers’ Liability Insurance. During the Term, the Company shall use commercially reasonable

efforts to maintain in effect Directors’ and Officers’ Liability Insurance in an amount determined by the Board, which shall

contain customary coverage for Executive and which will be on terms no less favorable than provided to other directors and executive

officers of the Company. Upon the Effective Date, the Company and Executive shall also enter into the Indemnification Agreement in the

form attached as Exhibit A hereto.

(g)

Paid Time Off Policy. Executive will be entitled to paid time off (“PTO”) in accordance with the policy

for U.S. - based senior management as in effect from time to time. Executive acknowledges and understands that the PTO policy applicable

to Executive as of the Effective Date provides for four (4) weeks paid time off plus U.S. holidays. The Company agrees that, notwithstanding

any future changes to the PTO policy for U.S. based senior management, the PTO policy applicable to Executive will be no less favorable

than the PTO policy in effect as of the Effective Date.

(h)

Other Benefits. Executive shall be eligible to participate in the employee benefit plans hereafter established and maintained

by the Company from time to time during the Term, which benefit plans are of general applicability to its similarly situated U.S. –

based senior management.

(i)

Withholding. All amounts payable to Executive under this Agreement shall be subject to all required federal, state and

local withholding, payroll and insurance taxes.

(j)

Board Discretion. Nothing in this Section 5 shall obligate the Board to implement any particular benefit plan or

prevent the Board from amending or terminating any benefit plan implemented.

Page 3 of 23

6.

Termination. Executive’s employment may be terminated and this Agreement terminated under the following circumstances:

(a)  Death.

Executive’s employment hereunder shall terminate upon her death.

(b)

Disability. The Company may terminate Executive’s employment if Executive becomes subject to a Disability. For purposes

of this Agreement, “Disability” means Executive is unable to perform the essential functions of her position, with

or without a reasonable accommodation, for a period of ninety (90) consecutive calendar days or one hundred twenty (120) non-consecutive

calendar days within any rolling twelve (12) month period because of physical, mental, or emotional incapacity, resulting from injury,

sickness, or disease, as determined by an independent physician selected by the Company.

(c)

Termination by Company for Cause. The Company may terminate Executive’s employment for “Cause.” For

purposes of this Agreement, “Cause” means Executive’s (i) commission of an act of fraud against the Company,

misappropriation of Company assets, embezzlement, theft, or the conviction of a crime involving drug abuse, violence, dishonesty, theft

or moral turpitude; (ii) material breach of this Agreement; (iii) continuing and material failure to comply with the policies and/or

directives of the Company; or (iv) failure to substantially perform the material duties Executive is required to perform under this Agreement

or to follow any specific lawful instructions of the Board (other than as a result of partial or total incapacity due to physical or

mental illness) which misconduct, breach or failure is not cured to the satisfaction of the Board or is not capable of being cured within

fifteen (15) days following the Company’s written notice to Executive describing in reasonable detail the misconduct, breach or

failure and the requirements to cure the misconduct, breach or failure, if capable of being cured.

(d)

Termination by the Company Without Cause. A termination of Executive’s employment by the Company for any reason, except

death, disability or Cause, will be deemed to be a termination “Without Cause.”

(e)  Termination

by Executive for Good Reason. Executive may terminate her employment for “Good Reason.” For purposes of

this Agreement, “Good Reason” means (i) without Executive’s written consent, a material reduction of her duties,

positions or responsibilities, including but not limited to removal of Executive as CFO; (ii) without Executive’s written consent, a

reduction by the Company in Base Salary as in effect immediately prior to such reduction; (iii) without Executive’s written

consent, relocation of her primary place of employment to a place more than fifty (50) miles from her principal residence; or (iv)

the Company’s material breach of this Agreement; provided that within thirty (30) days of the Company’s act or omission giving rise

to a resignation for Good Reason, Executive notifies the Company in writing of the act or omission, the Company fails to correct the

act or omission (to the extent curable) within thirty (30) days after receiving Executive’s written notice and Executive actually

terminates her employment within sixty (60) days after the date the Company receives Executive’s notice.

Page 4 of 23

(f)

Termination by Executive Without Good Reason. A resignation of Executive’s employment for any reason other than Good Reason

will be deemed to be a resignation “Without Good Reason.” Executive may terminate her employment at any time Without

Good Reason, upon thirty (30) days prior written notice to the Company, provided however, the Company may accelerate the date of such

termination to any date following the receipt of such written notice.

(g)

Termination by the Company due to Non-renewal. A termination of Executive’s employment by the Company due to the Company’s

non-renewal of this Agreement pursuant to Section 3, will not be deemed to be a termination for purposes of this Section 6.

(h)

Termination Date. The “Termination Date” means (i) if Executive’s employment is terminated by her death

under Section 6(a), the date of her death; (ii) if Executive’s employment is terminated on account of her Disability under Section

6(b), the date on which the Company provides Executive a written termination notice; (iii) if the Company terminates Executive’s

employment for Cause under Section 6(c), the date on which the Company provides Executive a written termination notice; (iv) if

the Company terminates Executive’s employment Without Cause under Section 6(d), the date on which the Company provides Executive

a written termination notice; (v) if Executive resigns her employment for Good Reason under Section 6(e), the date on which Executive

provides the Company a written termination notice; and (vi) if Executive resigns her employment Without Good Reason under Section

6(f), thirty (30) days after the date on which Executive provides the Company a written termination notice, unless accelerated by

the Company pursuant to Section 6(f) above.

(i)

Deemed Resignation. Immediately upon the termination of Executive’s employment with the Company for any reason, Executive

will be deemed to have resigned from all positions as an officer or director of the Company and its affiliates, along with any other

positions she may hold with or for the benefit of the Company and/or its affiliates. In furtherance of the preceding sentence, Executive

will execute and return to the Company all letters and documents that the Company may reasonably require in order to evidence such resignation(s),

but Executive’s failure to execute and return such documents will not have the effect of delaying or in any way invalidating the

resignation(s) provided for by the preceding sentence.

7.  Compensation

Upon Termination.

(a)

Termination by the Company for Cause or by Executive Without Good Reason. If Executive’s employment with the Company is

terminated pursuant to Sections 6(c), or 6(f), the Company shall pay or provide to Executive (i) any earned but unpaid

Base Salary as of the Termination Date; (ii) unpaid expense reimbursements as of the Termination Date; and (iii) any vested benefits

Executive may be entitled to under any employee benefit plan of the Company (collectively, the “Accrued Obligations”),

on or before the time required by law but in no event more than thirty (30) days after the Termination.

Page 5 of 23

(b)

Termination for Death or Disability. If Executive’s Employment is terminated by reason of Executive’s death pursuant

to Section 6(a) or Disability pursuant to Section 6(b), then the Company shall pay Executive or her estate or legal representative,

as the case may be the Accrued Obligations and any accrued but unpaid bonus earned through the Termination Date, on or before thirty

(30) days after the Termination Date.

(c)

Termination by the Company Without Cause or by Executive with Good Reason. If Executive’s employment is terminated by the

Company Without Cause pursuant to Section 6(d) or Executive terminates her employment for Good Reason pursuant to Section 6(e),

then Executive shall be entitled to the following:

(i)

The Company shall pay Executive the Accrued Obligations, on or before thirty (30) days after the Termination Date;

(ii)

The Company shall pay Executive her Base Salary then in effect for a period of six (6) month from the Termination Date (the “Severance

Period”), in accordance with the Company’s normal payroll practices in effect on the Termination Date;

(iii)

a pro-rata portion of Executive’s at-target Annual Bonus for the calendar year in which the termination occurs on or before ninety

(90) days after the Termination Date ; and

(iv)

continuation of health benefits for the Severance Period at Company expense, with such benefits provided either through COBRA reimbursement

or direct payment of premiums, at Executive’s election.

8. Change

in Control.

(a)

In the event of a Change in Control followed by Executive’s termination Without Cause or resignation for Good Reason within nine (9)

months of such Change of Control, Executive shall be entitled to receive: (i) all Accrued Obligations within thirty (30) days of the

Termination Date; (ii) nine (9) months of Base Salary paid in accordance with the Company’s normal payroll practices in effect on the

Termination Date; (ii) a pro-rata portion of Executive’s at-target Annual Bonus for the calendar year in which the termination

occurs within ninety (90) days of the Termination Date; and (iii) continuation of health benefits for nine (9) months at Company expense,

with such benefits provided either through COBRA reimbursement or direct payment of premiums, at Executive’s election.

(b)

For purposes of this Agreement, a “Change in Control” means (i) a sale of all or substantially all of the

Company’s assets; (ii) any merger, consolidation or other business combination transaction of the Company with or into another

corporation, entity or person, other than a transaction in which the holders of at least a majority of the shares of voting capital

stock of the Company outstanding immediately prior to such transaction continue to hold (either by such shares remaining outstanding

or by their being converted into shares of voting capital stock of the surviving entity) a majority of the total voting power

represented by the shares of voting capital stock of the Company (or the surviving entity) outstanding immediately after such

transaction; or (iii) the direct or indirect acquisition (including by way of a tender or exchange offer) by any person, or persons

acting as a group, of beneficial ownership or a right to acquire beneficial ownership of shares representing a majority of the

voting power of the then outstanding shares of capital stock of the Company.

Page 6 of 23

9. Section

409A.

(a)

This Agreement is intended to comply with Section 409A or an exemption thereunder and shall be construed and administered in accordance

with Section 409A.

(b)

All in-kind benefits provided and expenses eligible for reimbursement under this Agreement shall be provided by the Company or incurred

by Executive during the time periods set forth in this Agreement. All reimbursements shall be paid as soon as administratively practicable,

but in no event shall any reimbursement be paid after the last day of the taxable year following the taxable year in which the expense

was incurred. The amount of in-kind benefits provided or reimbursable expenses incurred in one taxable year shall not affect the in-kind

benefits to be provided or the expenses eligible for reimbursement in any other taxable year. Such right to reimbursement or in-kind

benefits is not subject to liquidation or exchange for another benefit.

(c)

To the extent that any of the payments or benefits provided for in Sections 7 or 8 are deemed to constitute

non-qualified deferred compensation benefits subject to Section 409A of the United States Internal Revenue Code (the

“Code”), the following interpretations apply to Section 7 or 8: Any termination of Executive’s

employment triggering payment of benefits under Section 7 or 8 must constitute a “separation from

service” under Section 409A(a)(2)(A)(i) of the Code and Treas. Reg. §1.409A-1(h) before distribution of such benefits

can commence. To the extent that the termination of Executive’s employment does not constitute a separation of service under Section

409A(a)(2)(A)(i) of the Code and Treas. Reg. §1.409A-1(h) (as the result of further services that are reasonably anticipated to

be provided by Executive to the Company or any of its parents, subsidiaries or affiliates at the time Executive’s employment

terminates), any benefits payable under Sections 7 or 8 that constitute deferred compensation under Section 409A of

the Code shall be delayed until after the date of a subsequent event constituting a separation of service under Section

409A(a)(2)(A)(i) of the Code and Treas. Reg. §1.409A-1(h). For purposes of clarification, this Section 9(b) shall not

cause any forfeiture of benefits on Executive’s part but shall only act as a delay until such time as a “separation from

service” occurs. Further, if Executive is a “specified employee” (as that term is used in Section 409A

of the Code and regulations and other guidance issued thereunder) on the date her separation from service becomes effective, any

benefits payable under Section 7 or 8 that constitute non-qualified deferred compensation under Section 409A of the

Code shall be delayed until the earlier of (i) the business day following the six-month anniversary of the date her separation from

service becomes effective; and (ii) the date of Executive’s death, but only to the extent necessary to avoid such penalties under

Section 409A of the Code. On the earlier of (i) the business day following the six (6) month anniversary of the date her separation

from service becomes effective; and (ii) Executive’s death, the Company shall pay Executive in a lump sum the aggregate value of the

non-qualified deferred compensation that the Company otherwise would have paid Executive prior to that date under Sections 7

or 8 of this Agreement. It is intended that each installment of the payments and benefits provided under Section 7 of

this Agreement shall be treated as a separate “payment” for purposes of Section 409A of the Code. Neither the

Company nor Executive shall have the right to accelerate or defer the delivery of any such payments or benefits except to the extent

specifically permitted or required by Section 409A of the Code.

Page 7 of 23

10.  Section

280G.

(a)

If any of the payments or benefits received or to be received by Executive (including, without limitation, any payment or benefits received

in connection with a Change in Control or Executive’s termination of employment, whether pursuant to the terms of this Agreement

or any other plan, arrangement, or agreement, or otherwise) (all such payments collectively referred to herein as the “280G

Payments”) constitute “parachute payments” within the meaning of Section 280G of the Code and would, but

for this Section 10, be subject to the excise tax imposed under Section 4999 of the Code (the “Excise Tax”),

then such 280G Payments shall be reduced in a manner determined by the Company (by the minimum possible amounts) that is consistent with

the requirements of Section 409A until no amount payable to Executive will be subject to the Excise Tax. If two economically equivalent

amounts are subject to reduction but are payable at different times, the amounts shall be reduced (but not below zero) on a pro rata

basis.

(b)

All calculations and determinations under this Section 10 shall be made by an independent accounting firm or independent tax counsel

appointed by the Company (the “Tax Counsel”) whose determinations shall be conclusive and binding on the Company and

Executive for all purposes. For purposes of making the calculations and determinations required by this Section 10, the Tax Counsel

may rely on reasonable, good faith assumptions and approximations concerning the application of Section 280G and Section 4999 of the

Code. The Company and Executive shall furnish the Tax Counsel with such information and documents as the Tax Counsel may reasonably request

in order to make its determinations under this Section 10. The Company shall bear all costs the Tax Counsel may reasonably incur

in connection with its services.

11.  Confidential

Information.

(a)

As used in this Agreement, “Confidential Information” means information belonging to the Company which is of

value to the Company in the course of conducting its business and the disclosure of which could result in a competitive or other

disadvantage to the Company. Confidential Information includes, without limitation, financial information, reports, and forecasts;

inventions, improvements and other intellectual property; trade secrets; know-how; designs, processes or formulae; software; market

or sales information or plans; customer lists; business plans, prospects and opportunities (such as possible acquisitions or

dispositions of businesses or facilities) which have been discussed or considered by the management of the Company. Confidential

Information includes information developed by Executive in the course of Executive’s employment by the Company, as well as other

information to which Executive may have access in connection with her employment. Confidential Information also includes the

confidential information of others with which the Company has a business relationship. Notwithstanding the foregoing, Confidential

Information does not include (i) information which now or in the future comes into the public domain, unless due to breach of

Executive’s duties under this Section 11(a); (ii) information which is disclosed to Executive by others who are not, to

Executive’s actual knowledge, under obligation of nondisclosure to the Company; (iii) information which is independently developed

by Executive without breach of Executive’s duties under this Section 11(a); or (iv) information which is disclosed by the

Company to others without obligation of confidentiality.

Page 8 of 23

(b)

At all times, both during Executive’s employment with the Company and after its termination, Executive will keep in confidence and trust

all Confidential Information, and will not use or disclose for her own benefit or the benefit of any other Person any such Confidential

Information without the written consent of the Company, except as may be necessary in the ordinary course of performing Executive’s duties

to the Company.

11.

Documents, Records, Etc. All documents, records, data, apparatus, equipment and other physical property, whether or not

pertaining to Confidential Information, which are furnished to Executive by the Company or are produced by Executive in connection with

Executive’s employment will be and remain the sole property of the Company. Executive will return to the Company all such materials and

property as and when requested by the Company. In any event, Executive will return all such materials and property immediately upon termination

of Executive’s employment for any reason. Executive will not retain any such material or property or any copies thereof after the termination

of her employment.

12.

Non-Competition. During the Term and in the event this Agreement is terminated by the Company for Cause or by Executive

without Good Reason, for a period of two (2) years from the Termination Date (the “Restricted Period”) Executive will

not, directly or indirectly, whether as owner, partner, shareholder, consultant, agent, employee, co-venturer or otherwise, engage, prepare

to engage, participate, assist or invest in any Competing Business anywhere in the United States or any other geographic area in which

the Company is actively distributing its products or providing its services as of the Termination Date. Notwithstanding the foregoing,

(a) Executive may own up to two percent (2%) of the outstanding stock of a publicly held corporation which constitutes or is affiliated

with a Competing Business; and (b) Executive may be employed by a large organization which is engaged in a Competing Business as its

non-primary business, so long as Executive is not involved with or assisting such Competing Business, and so long as Executive does not

breach her obligations regarding Confidential Information.

13.

No Solicitation. During the Restricted Period, Executive shall not, directly or indirectly, take any of the following actions,

and, to the extent Executive owns, manages, operates, controls, is employed by or participates in the ownership, management, operation

or control of, or is connected in any manner with, any business, Executive shall use her best efforts to ensure that such business does

not take any of the following actions:

(a)

persuade or attempt to persuade any Customer, Prospective Customer or Supplier to cease doing business with the Company, or to reduce

the amount of business it does with the Company;

(b)

solicit or service for herself, or for any Person, the business of a Customer, Prospective Customer or Supplier in order to provide goods

or services that are competitive with the goods and services provided by the Company;

(c)

persuade or attempt to persuade any Service Provider to cease providing services to the Company; or

Page 9 of 23

(d)

solicit for hire or hire for herself, or for any third party, any Service Provider.

(e)  The following definitions are applicable to Sections 13 and 14:

(i)

“Competing Business” means the business of developing, manufacturing, marketing and selling surgical robotic systems

and ancillary products and services and any other business in which the services which the Company is engaged in as of the Termination

Date.

(ii)

“Customer” means any Person that purchased goods or services from the Company at any time within two (2) years prior

to the date of the solicitation prohibited by Sections 14(a) or (b).

(iii)

“Prospective Customer” means any Person with whom the Company met or to whom the Company presented for the purpose

of soliciting the Person to become a Customer of the Company within six (6) months prior to the date of the solicitation prohibited by

Sections 14(a) or (b).

(iv)

“Service Provider” means any Person who is an employee or independent contractor of the Company or the Company or

who was within twelve (12) months preceding the solicitation prohibited by Sections 14(a) or (b) an employee or independent

contractor of the Company or the Company.

(v)

“Supplier” means any Person that sold goods or services to the Company at any time within twelve (12) months prior

to the date of the solicitation prohibited by Sections 14(a) or (b).

(vi)

“Person” means an individual, a sole proprietorship, a corporation, a limited liability company, a partnership,

an association, a trust, or other business entity, whether or not incorporated.

15.  Intellectual

Property.

(a)

All creations, inventions, ideas, designs, copyrightable materials, trademarks, and other technology and rights (and any related

improvements or modifications), whether or not subject to patent or copyright protection (collectively,

“Creations”), relating to any activities of the Company which are conceived by Executive or developed by

Executive in the course of her employment with the Company, whether prior to or during the Term, whether conceived alone or with

others and whether or not conceived or developed during regular business hours, shall be the sole property of the Company and, to

the maximum extent permitted by applicable law, shall be deemed “works made for hire” as that term is used in the

United States Copyright Act.

Page 10 of 23

(b)

To the extent, if any, that Executive retains any right, title or interest with respect to any Creations delivered to the Company or

related to her employment with the Company, Executive hereby grants to the Company an irrevocable, paid-up, transferable, sub-licensable,

worldwide right and license: (i) to modify all or any portion of such Creations, including, without limitation, the making of additions

to or deletions from such Creations, regardless of the medium (now or hereafter known) into which such Creations may be modified and

regardless of the effect of such modifications on the integrity of such Creations; and (ii) to identify Executive, or not to identify

her, as one or more authors of or contributors to such Creations or any portion thereof, whether or not such Creations or any portion

thereof have been modified. Executive further waives any “moral” rights, or other rights with respect to attribution

of authorship or integrity of such Creations that she may have under any applicable law, whether under copyright, trademark, unfair competition,

defamation, and right of privacy, contract, tort or other legal theory.

(c)

Executive will promptly inform the Company of any Creations. Executive will also allow the Company to inspect any Creations she conceives

or develops within one (1) year after the termination of her employment for any reason to determine if they are based on Confidential

Information. Executive shall (whether during her employment or after the termination of her employment) execute such written instruments

and do other such acts as may be necessary in the opinion of the Company or its counsel to secure the Company’s rights in the Creations,

including obtaining a patent, registering a copyright, or otherwise (and Executive hereby irrevocably appoints the Company and any of

its officers as her attorney in fact to undertake such acts in her name). Executive’s obligation to execute written instruments

and otherwise assist the Company in securing its rights in the Creations will continue after the termination of her employment for any

reason. The Company shall reimburse Executive for any out-of-pocket expenses (but not attorneys’ fees) she incurs in connection with

her compliance with this Section 15(c).

16.

Acknowledgement. Executive understands that the restrictions set forth in Sections 11, 12, 13, 14,

15 and 16 of this Agreement are intended to protect the Company’s interest in its Confidential Information, goodwill and

established employee and customer relationships and agrees that such restrictions are reasonable and appropriate for this purpose.

17.  Representations

and Covenants of Executive Regarding Prior Employment.

(a)

Executive represents that her performance of all of the terms of this Agreement does not and will not breach any arrangement to keep

in confidence information acquired by Executive in confidence or in trust prior to Executive’s employment by the Company. Executive

represents that she has not entered into, and agrees not to enter into, any agreement either oral or written in conflict herewith.

(b)

Executive understands as part of the consideration for this Agreement and for Executive’s employment by the Company, that

Executive has not brought and will not bring with Executive to the Company, or use in the performance of Executive’s duties

and responsibilities for the Company or otherwise on its behalf, any materials or documents of a former employer or other owner

which are generally not available to the public, unless Executive has obtained written authorization from the former employer or

other owner for their possession and use and has provided the Company with a copy thereof.

(c)

Executive understands that, during her employment for the Company, she is not to breach any obligation of confidentiality that Executive

has to a former employer or any other person or entity and agrees to comply with such understanding.

Page 11 of 23

17.

Survival. The provisions of Sections 10, 11, 12, 13, 14, 15, 16, 17,

19, 24 and 26 of this Agreement shall survive its expiration or termination.

18.  Disputes.

(a)

The parties agree to resolve any dispute arising under or relating to the interpretation or enforcement of this Agreement, Executive’s

employment or the termination of Executive’s employment in the Supreme Court for the State of New York, New York County or the United

States District Court for the Southern District of New York, and hereby consent to the exclusive jurisdiction of such courts. Accordingly,

with respect to any such court action, Executive and the Company each (i) submits to the personal jurisdiction of these courts; (ii)

consents to service of process under the notice provisions set forth in Section 23 of this Agreement; (iii) waives any other requirement

(whether imposed by statute, rule of court, or otherwise) with respect to personal jurisdiction or service of process; and (iv) waives

any objection to jurisdiction based on improper venue or improper jurisdiction.

(b)

Notwithstanding anything else provided in this Agreement, Executive agrees that it would be difficult to measure any damages caused to

the Company which might result from any breach by Executive of Sections, 11, 12, 13, 14 and/or 15

of this Agreement. Accordingly, if Executive breaches or proposes to breach, any term of Sections 11, 12, 13,

14 and/or 15 of this Agreement, the Company shall be entitled, in addition to all other remedies that it may have, to a

temporary and preliminary injunction or other appropriate equitable relief to restrain any such breach without showing or providing any

actual damage to the Company from any court having competent jurisdiction over Executive.

(c)

BOTH THE COMPANY AND EXECUTIVE HEREBY WAIVE ANY RIGHT TO A TRIAL BY JURY TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE FEDERAL OR STATE

LAW.

(d)

The prevailing party shall be entitled to reasonable attorneys’ fees and costs from the non-prevailing party in connection with any action

filed under this Section 18.

19.

Integration. This Agreement constitutes the entire agreement between the parties with respect to the subject matter hereof

and supersedes all prior agreements between the parties concerning such subject matter.

20.  Successors.

This Agreement shall inure to the benefit of and be enforceable by Executive’s personal representatives, executors, administrators,

heirs, distributees, devisees and legatees. In the event of Executive’s death after her termination of employment but prior to the

completion by the Company of all payments due her under this Agreement, the Company shall continue such payments to Executive’s

beneficiary designated in writing to the Company prior to her death (or to her estate, if Executive fails to make such designation).

The Company shall require any successor to the Company to expressly assume and agree to perform this Agreement in the same manner

and to the same extent that the Company would be required to perform it if no such succession had taken place.

Page 12 of 23

21.

Enforceability. If any portion or provision of this Agreement (including, without limitation, any portion or provision

of any section of this Agreement) shall to any extent be declared illegal or unenforceable by a court of competent jurisdiction, then

the remainder of this Agreement, or the application of such portion or provision in circumstances other than those as to which it is

so declared illegal or unenforceable, shall not be affected thereby, and each portion and provision of this Agreement shall be valid

and enforceable to the fullest extent permitted by law.

22.

Waiver. No waiver of any provision hereof shall be effective unless made in writing and signed by the waiving party. The

failure of any party to require the performance of any term or obligation of this Agreement, or the waiver by any party of any breach

of this Agreement, shall not prevent any subsequent enforcement of such term or obligation or be deemed a waiver of any subsequent breach.

23.

Notices. Any notices, requests, demands and other communications provided for by this Agreement shall be sufficient if

in writing and delivered in person or sent by a nationally recognized overnight courier service, to Executive at the last address Executive

has filed in writing with the Company or, in the case of the Company, at its main offices, attention of the Chief Executive Officer.

Notices shall be effective on receipt.

24.

Amendment. This Agreement may be amended or modified only by a written instrument signed by Executive and by a duly authorized

representative of the Company.

25.

Governing Law. This Agreement shall be construed under and be governed in all respects by the laws of the Commonwealth

of Massachusetts for contracts to be performed in that state and without giving effect to the conflict of laws principles of Massachusetts

or any other state.

26.

“Company” Defined. As used in this Agreement, the term the “Company” shall mean the Company,

its direct and indirect subsidiaries and divisions.

27.

Counterparts. This Agreement may be executed in any number of counterparts, including by facsimile, .PDF or other electronic

transmission (which shall be deemed to be an original), each of which when so executed and delivered shall be taken to be an original;

but such counterparts shall together constitute one and the same document.

[SIGNATURE

PAGE FOLLOWS]

Page 13 of 23

IN

WITNESS WHEREOF, the parties hereto have executed this Agreement effective as of the Effective Date.

THE COMPANY:

SS INNOVATIONS INTERNATIONAL, INC.

By:

/s/ Sudhir Srivastava

Name:

Sudhir Srivastava, M.D.

Title:

Chairman and Chief Executive Officer

EXECUTIVE:

/s/ Sarah M. Romano

Sarah M. Romano

Page 14 of 23

EXHIBIT

A

Indemnification

Agreement

[See

attached.]

Page 15 of 23

INDEMNIFICATION AGREEMENT

This INDEMNIFICATION AGREEMENT

(this “Agreement”), dated as of the 3rd day of August, 2026, is made by and between SS INNOVATIONS INTERNATIONAL,

INC., a Florida corporation (the “Company”) and SARAH A. ROMANO (the “Indemnitee”).

RECITALS

A. The Company

and the Indemnitee recognize that the present state of the law is too uncertain to provide the Company’s officers and directors

with adequate and reliable advance knowledge or guidance with respect to the legal risks and potential liabilities to which they may become

personally exposed as a result of performing their duties for the Company;

B. The Company

and the Indemnitee are aware of the substantial growth in the number of lawsuits filed against corporate officers and directors in connection

with their activities in such capacities and by reason of their status as such;

C. The Company

and the Indemnitee recognize that the cost of defending against such lawsuits, whether or not meritorious, is typically beyond the financial

resources of most officers and directors of the Company;

D. The Company

and the Indemnitee recognize that the legal risks and potential liabilities, and the threat thereof, associated with proceedings filed

against the officers and directors of the Company bear no reasonable relationship to the amount of compensation received by the Company’s

officers and directors;

E. The Company,

after reasonable investigation prior to the date hereof, has determined that the liability insurance coverage available to the Company

as of the date hereof may be inadequate, unreasonably expensive or both. The Company believes, therefore, that the interest of the Company

and its current and future shareholders would be best served by a combination of (i) such insurance as the Company may obtain pursuant

to the Company’s obligations hereunder; and (ii) a contract with its officers and directors, including the Indemnitee, to indemnify

them to the fullest extent permitted by law (as in effect on the date hereof, or, to the extent any amendment may expand such permitted

indemnification, as hereafter in effect) against personal liability for actions taken in the performance of their duties to the Company;

F. Section

607.0850 of the Florida Business Corporation Act empowers Florida corporations to indemnify their officers and directors and further states

that the indemnification provided by Section 607.0850 shall not be deemed exclusive of any other rights to which those seeking indemnification

may be entitled under the Articles of Incorporation, Bylaws or any agreement, vote of shareholders or disinterested directors or otherwise,

both as to action in an official capacity and as to action in another capacity while holding such office; thus, Section 607.0850 does

not by itself limit the extent to which the Company may indemnify persons serving as its officers and directors;

Page 16 of 23

G. The Company’s

Articles of Incorporation and Bylaws, as amended and restated, authorize the indemnification of the officers and directors of the Company

in excess of that expressly permitted by Section 607.0850;

H. The Board

of Directors of the Company has concluded that, to retain and attract talented and experienced individuals to serve as officers and directors

of the Company and to encourage such individuals to take the business risks necessary for the success of the Company, it is necessary

for the Company to contractually indemnify its officers and directors, and to assume for itself liability for expenses and damages in

connection with claims against such officers and directors in connection with their service to the Company, and has further concluded

that the failure to provide such contractual indemnification could result in great harm to the Company and its shareholders;

I. The Company

desires and has requested the Indemnitee to serve or continue to serve as a director or officer of the Company, free from undue concern

for the risks and potential liabilities associated with such services to the Company; and

J. The Indemnitee

is willing to serve, or continue to serve, the Company, provided, and on the expressed condition, that the Indemnitee is furnished with

the indemnification provided for herein.

AGREEMENT

NOW, THEREFORE,

for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Company and Indemnitee agree as

follows:

1. DEFINITIONS.

(a) “EXPENSES”

means, for the purposes of this Agreement, all direct and indirect costs of any type or nature whatsoever (including, without limitation,

any fees and disbursements of Indemnitee’s counsel, accountants and other experts and other out-of-pocket costs) actually and reasonably

incurred by the Indemnitee in connection with the investigation, preparation, defense or appeal of a Proceeding; provided, however, that

Expenses shall not include judgments, fines, penalties or amounts paid in settlement of a Proceeding.

(b) “PROCEEDING”

means, for the purposes of this Agreement, any threatened, pending or completed action or proceeding, whether civil, criminal, administrative

or investigative (including an action brought by or in the right of the Company) in which Indemnitee may be or may have been involved

as a party or otherwise, by reason of the fact that Indemnitee is or was a director or officer of the Company, by reason of any action

taken by Indemnitee or of any inaction on his or her part while acting as such director or officer or by reason of the fact that he or

she is or was serving at the request of the Company as a director, officer, employee or agent of another foreign or domestic corporation,

partnership, joint venture, trust or other enterprise, or was a director or officer of the foreign or domestic corporation which was a

predecessor corporation to the Company or of another enterprise at the request of such predecessor corporation, whether or not he or she

is serving in such capacity at the time any liability or expense is incurred for which indemnification or reimbursement can be provided

under this Agreement.

Page 17 of 23

2. AGREEMENT

TO SERVE. Indemnitee agrees to serve or continue to serve as a director or officer of the Company to the best of his or her abilities

at the will of the Company or under separate contract, if such contract exists, for so long as Indemnitee is duly elected or appointed

and qualified or until such time as the Indemnitee tenders his or her resignation in writing. Nothing contained in this Agreement is intended

to create in Indemnitee any right to continued employment.

3. INDEMNIFICATION.

(a) THIRD

PARTY PROCEEDINGS. The Company shall indemnify Indemnitee against Expenses, judgments, fines, penalties or amounts paid in settlement

(if the settlement is approved in advance by the Company) actually and reasonably incurred by Indemnitee in connection with a Proceeding

(other than a Proceeding by or in the right of the Company) if Indemnitee acted in good faith and in a manner Indemnitee reasonably believed

to be in the best interests of the Company, and, with respect to any criminal action or proceeding, had no reasonable cause to believe

Indemnitee’s conduct was unlawful. The termination of any Proceeding by judgment, order, settlement, conviction, or upon a plea

of NOLO CONTENDERE or its equivalent, shall not, of itself, create a presumption that Indemnitee did not act in good faith and in a manner

which Indemnitee reasonably believed to be in the best interests of the Company, or, with respect to any criminal Proceeding, had no reasonable

cause to believe that Indemnitee's conduct was unlawful.

(b) PROCEEDINGS

BY OR IN THE RIGHT OF THE COMPANY. To the fullest extent permitted by law, the Company shall indemnify Indemnitee against Expenses

and amounts paid in settlement, actually and reasonably incurred by Indemnitee in connection with a Proceeding by or in the right of the

Company to procure a judgment in its favor if Indemnitee acted in good faith and in a manner Indemnitee reasonably believed to be in the

best interests of the Company and its shareholders. Notwithstanding the foregoing, no indemnification shall be made in respect of any

claim, issue or matter as to which Indemnitee shall have been adjudged liable to the Company in the performance of Indemnitee’s

duty to the Company and its shareholders unless and only to the extent that the court in which such action or Proceeding is or was pending

shall determine upon application that, in view of all the circumstances of the case, Indemnitee is fairly and reasonably entitled to indemnity

for Expenses and then only to the extent that the court shall determine.

(c) SCOPE.

Notwithstanding any other provision of this Agreement but subject to Section 3(b) and Section 14(b), the Company shall indemnify

the Indemnitee to the fullest extent permitted by law, notwithstanding that such indemnification is not specifically authorized by other

provisions of this Agreement, the Company’s Articles of Incorporation, the Company’s Bylaws or by statute.

4. LIMITATIONS

ON INDEMNIFICATION. Any other provision herein to the contrary notwithstanding, the Company shall not be obligated pursuant to the

terms of this Agreement:

(a) EXCLUDED

ACTS. To indemnify Indemnitee for any acts or omissions or transactions from which a director may not be relieved of liability under

applicable law;

Page 18 of 23

(b) EXCLUDED

INDEMNIFICATION PAYMENTS. To indemnify or advance Expenses in violation of any prohibition or limitation on indemnification under

the statutes, regulations or rules promulgated by any state or federal regulatory agency having jurisdiction over the Company;

(c) CLAIMS

INITIATED BY INDEMNITEE. To indemnify or advance Expenses to Indemnitee with respect to Proceedings or claims initiated or brought

voluntarily by Indemnitee and not by way of defense, except with respect to Proceedings brought to establish or enforce a right to indemnification

under this Agreement or any other statute or law or otherwise as required under Section 607.0850 of the Florida Business Corporation Act,

but such indemnification or advancement of Expenses may be provided by the Company in specific cases if the Board of Directors has approved

the initiation or bringing of such suit;

(d) LACK

OF GOOD FAITH. To indemnify Indemnitee for any Expenses incurred by the Indemnitee with respect to any Proceeding instituted by Indemnitee

to enforce or interpret this Agreement, if a court of competent jurisdiction determines that each of the material assertions made by the

Indemnitee in such Proceeding was not made in good faith or was frivolous;

(e) INSURED

CLAIMS. To indemnify Indemnitee for Expenses or liabilities of any type whatsoever (including, but not limited to, judgments, fines,

ERISA excise taxes or penalties, and amounts paid in settlement) which have been paid directly to or on behalf of Indemnitee by an insurance

carrier under a policy of directors’ and officers’ liability insurance maintained by the Company or any other policy of insurance

maintained by the Company or Indemnitee; or

(f) CLAIMS

UNDER SECTION 16(b). To indemnify Indemnitee for Expenses and the payment of profits arising from the purchase and sale by Indemnitee

of securities in violation of Section 16(b) of the Securities Exchange Act of 1934, as amended, or any similar successor statute.

5. DETERMINATION

OF RIGHT TO INDEMNIFICATION. Upon receipt of a written claim addressed to the Board of Directors for indemnification pursuant to Section

3, the Company shall determine by any of the methods set forth in Section 607.0850 of the Florida Business Corporation Act whether

Indemnitee has met the applicable standards of conduct which makes it permissible under applicable law to indemnify Indemnitee. If such

standards have been met and a claim under Section 3 is not paid in full by the Company within ninety (90) days after such written

claim has been received by the Company, the Indemnitee may at any time thereafter bring suit against the Company to recover the unpaid

amount of the claim and, unless such action is dismissed by the court as frivolous or brought in bad faith, the Indemnitee shall be entitled

to be paid also the expense of prosecuting such claim. The court in which such action is brought shall determine whether Indemnitee or

the Company shall have the burden of proof concerning whether Indemnitee has or has not met the applicable standard of conduct.

6. ADVANCEMENT

AND REPAYMENT OF EXPENSES. Subject to Section 4 hereof, the Expenses incurred by Indemnitee in defending and investigating

any Proceeding shall be paid by the Company in advance of the final disposition of such Proceeding within thirty (30) days after receiving

from Indemnitee the copies of invoices presented to Indemnitee for such Expenses, if Indemnitee shall provide an undertaking to the Company

to repay such amount to the extent it is ultimately determined that Indemnitee is not entitled to indemnification. In determining whether

or not to make an advance hereunder, the ability of Indemnitee to repay shall not be a factor. Notwithstanding the foregoing, in a proceeding

brought by the Company directly, in its own right (as distinguished from an action bought derivatively or by any receiver or trustee),

the Company shall not be required to make the advances called for hereby if the Board of Directors determines, in its sole discretion,

that it does not appear that Indemnitee has met the standards of conduct which make it permissible under applicable law to indemnify Indemnitee

and the advancement of Expenses would not be in the best interests of the Company and its shareholders.

Page 19 of 23

7. PARTIAL

INDEMNIFICATION. If the Indemnitee is entitled under any provision of this Agreement to indemnification or advancement by the Company

of some or a portion of any Expenses or liabilities of any type whatsoever (including, but not limited to, judgments, fines, penalties,

and amounts paid in settlement) incurred by him in the investigation, defense, settlement or appeal of a Proceeding, but is not entitled

to indemnification or advancement of the total amount thereof, the Company shall nevertheless indemnify or pay advancements to the Indemnitee

for the portion of such Expenses or liabilities to which the Indemnitee is entitled.

8. NOTICE

TO COMPANY BY INDEMNITEE. Indemnitee shall notify the Company in writing of any matter with respect to which Indemnitee intends to

seek indemnification hereunder as soon as reasonably practicable following the receipt by Indemnitee of written notice thereof; provided,

however, that any delay in so notifying the Company shall not constitute a waiver by Indemnitee of her rights hereunder. The written notification

to the Company shall be addressed to the Board of Directors and shall include a description of the nature of the Proceeding and the facts

underlying the Proceeding and be accompanied by copies of any documents filed with the court in which the Proceeding is pending. In addition,

Indemnitee shall give the Company such information and cooperation as it may reasonably require and as shall be within Indemnitee’s

power.

9. MAINTENANCE OF LIABILITY INSURANCE.

(a) Subject

to Section 4 hereof, the Company hereby agrees that so long as Indemnitee shall continue to serve as a director or officer of the

Company and thereafter so long as Indemnitee shall be subject to any possible Proceeding, the Company, subject to Section 9(b),

shall use reasonable commercial efforts to obtain and maintain in full force and effect directors’ and officers’ liability

insurance (“D&O Insurance”) which provides Indemnitee the same rights and benefits as are accorded to the most

favorably insured of the Company’ directors, if Indemnitee is a director; or of the Company’s officers, if Indemnitee is not

a director of the Company but is an officer.

(b) Notwithstanding

the foregoing, the Company shall have no obligation to obtain or maintain D&O Insurance if the Company determines in good faith that

such insurance is not reasonably available, the premium costs for such insurance are disproportionate to the amount of coverage provided,

the coverage provided by such insurance is limited by exclusions so as to provide an insufficient benefit, or the Indemnitee is covered

by similar insurance maintained by a subsidiary or parent of the Company.

(c) If, at the

time of the receipt of a notice of a claim pursuant to Section 8 hereof, the Company has D&O Insurance in effect, the Company

shall give prompt notice of the commencement of such Proceeding to the insurers in accordance with the procedures set forth in the respective

policies. The Company shall thereafter take all necessary or desirable action to cause such insurers to pay, on behalf of the Indemnitee,

all amounts payable as a result of such Proceeding in accordance with the terms of such policies.

Page 20 of 23

10. DEFENSE

OF CLAIM. In the event that the Company shall be obligated under Section 6 hereof to pay the Expenses of any Proceeding against

Indemnitee, the Company, if appropriate, shall be entitled to assume the defense of such Proceeding, with counsel approved by Indemnitee,

which approval shall not be unreasonably withheld, upon the delivery to Indemnitee of written notice of its election to do so. After delivery

of such notice, approval of such counsel by Indemnitee and the retention of such counsel by the Company, the Company will not be liable

to Indemnitee under this Agreement for any fees of counsel subsequently incurred by Indemnitee with respect to the same Proceeding, provided

that (i) Indemnitee shall have the right to employ counsel in any such Proceeding at Indemnitee’s expense; and (ii) if (A) the employment

of counsel by Indemnitee has been previously authorized by the Company, or (B) Indemnitee shall have reasonably concluded that there may

be a conflict of interest between the Company and the Indemnitee in the conduct of such defense or (C) the Company shall not, in fact,

have employed counsel to assume the defense of such Proceeding, then the fees and expenses of Indemnitee’s counsel shall be at the

expense of the Company.

11. ATTORNEYS’

FEES. In the event that Indemnitee or the Company institutes an action to enforce or interpret any terms of this Agreement, the Company

shall reimburse Indemnitee for all of the Indemnitee’s reasonable fees and expenses in bringing and pursuing such action or defense,

unless as part of such action or defense, a court of competent jurisdiction determines that the material assertions made by Indemnitee

as a basis for such action or defense were not made in good faith or were frivolous.

12. CONTINUATION

OF OBLIGATIONS. All agreements and obligations of the Company contained herein shall continue during the period the Indemnitee is

a director or officer of the Company, or is or was serving at the request of the Company as a director, officer, fiduciary, employee or

agent of another corporation, partnership, joint venture, trust or other enterprise, and shall continue thereafter so long as the Indemnitee

shall be subject to any possible proceeding by reason of the fact that Indemnitee served in any capacity referred to herein.

13. SUCCESSORS

AND ASSIGNS. This Agreement establishes contract rights that shall be binding upon, and shall inure to the benefit of, the successors,

assigns, heirs and legal representatives of the parties hereto.

14. NON-EXCLUSIVITY.

(a) The provisions

for indemnification and advancement of expenses set forth in this Agreement shall not be deemed to be exclusive of any other rights that

the Indemnitee may have under any provision of law, the Company’s Articles of Incorporation or Bylaws, the vote of the Company’s

shareholders or disinterested directors, other agreements or otherwise, both as to action in the Indemnitee’s official capacity

and action in another capacity while occupying the Indemnitee’s position as a director or officer of the Company.

(b) In the event

of any changes, after the date of this Agreement, in any applicable law, statute, or rule which expand the right of a Florida corporation

to indemnify its officers and directors, the Indemnitee’s rights and the Company’s obligations under this Agreement shall

be expanded to the full extent permitted by such changes. In the event of any changes in any applicable law, statute or rule, which narrow

the right of a Florida corporation to indemnify a director or officer, such changes, to the extent not otherwise required by such law,

statute or rule to be applied to this Agreement, shall have no effect on this Agreement or the parties’ rights and obligations hereunder.

Page 21 of 23

15. EFFECTIVENESS

OF AGREEMENT. To the extent that the indemnification permitted under the terms of certain provisions of this Agreement exceeds the

scope of the indemnification provided for in the Florida Statutes, such provisions shall not be effective unless and until the Company’s

Articles of Incorporation authorize such additional rights of indemnification. In all other respects, the balance of this Agreement shall

be effective as of the date set forth on the first page and may apply to acts of omissions of Indemnitee which occurred prior to such

date if Indemnitee was an officer, director, employee or other agent of the Company, or was serving at the request of the Company as a

director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, at the time such act

or omission occurred.

16. SEVERABILITY.

Nothing in this Agreement is intended to require or shall be construed as requiring the Company to do or fail to do any act in violation

of applicable law. The Company’s inability, pursuant to court order, to perform its obligations under this Agreement shall not constitute

a breach of this Agreement. The provisions of this Agreement shall be severable as provided in this Section 16. If this Agreement

or any portion hereof shall be invalidated on any ground by any court of competent jurisdiction, then the Company shall nevertheless indemnify

Indemnitee to the full extent permitted by any applicable portion of this Agreement that shall not have been invalidated, and the balance

of this Agreement not so invalidated shall be enforceable in accordance with its terms.

17. GOVERNING

LAW. This Agreement shall be interpreted and enforced in accordance with the laws of the State of Florida, without reference to its

conflict of law principals. To the extent permitted by applicable law, the parties hereby waive any provisions of law which render any

provision of this Agreement unenforceable in any respect.

18. NOTICES.

All notices, requests, demands and other communications under this Agreement shall be in writing and shall be deemed duly given (i) if

delivered by hand; or (ii) sent by recognized overnight courier. Notices shall be deemed given upon receipt. Addresses for notice to either

party are as shown on the signature page of this Agreement, or as subsequently modified by written notice.

19. MUTUAL

ACKNOWLEDGMENT. Both the Company and Indemnitee acknowledge that in certain instances, federal law or applicable public policy may

prohibit the Company from indemnifying its directors and officers under this Agreement or otherwise. Indemnitee understands and acknowledges

that the Company has undertaken or may be required in the future to undertake with the appropriate state or federal regulatory agency

to submit for approval any request for indemnification, and has undertaken or may be required in the future to undertake with the Securities

and Exchange Commission to submit the question of indemnification to a court in certain circumstances for a determination of the Company’s

right under public policy to indemnify Indemnitee.

20 COUNTERPARTS.

This Agreement may be executed in one or more counterparts (including by facsimile, .PDF or other electronic transmission), each of which

shall constitute an original.

21. AMENDMENT

AND TERMINATION. No amendment, modification, termination or cancellation of this Agreement shall be effective unless in writing signed

by both parties hereto.

Page 22 of 23

IN WITNESS WHEREOF, the

parties have executed this Agreement as of the day and year set forth above.

THE COMPANY:

SS INNOVATIONS INTERNATIONAL, INC.

By:

Sudhir Srivastava, M.D.,

Chief Executive Officer

Address for Notices:

405, 3rd Floor, iLabs Info Technology Centre

Udyog Vihar, Phase III

Gurugram, Haryana, India 122016

Attention: Chief Executive Officer

INDEMNITEE:

Sarah A. Romano

Address for Notices:

Page 23 of 23

EX-99.1 — PRESS RELEASE, DATED JULY 14, 2026

EX-99.1

Filename: ea029760101ex99-1.htm · Sequence: 3

Exhibit 99.1

SS Innovations Appoints Sarah M. Romano as Chief

Financial Officer

Veteran medtech finance executive brings extensive

public company and capital markets experience to support the Company’s next phase of global growth

Fort Lauderdale, FL – July 14, 2026

– SS Innovations International, Inc. (the “Company” or “SS

Innovations”) (Nasdaq: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable

and accessible to a global population, today announced the appointment of Sarah M. Romano as Chief Financial Officer, effective August

3, 2026. Ms. Romano will be based in the United States.

Dr. Sudhir Srivastava, Chairman of the Board and

Chief Executive Officer of SS Innovations, commented, “We are thrilled to welcome Sarah as our Chief Financial Officer at this critical

moment in our growth journey. As we continue our global expansion, including pursuing U.S. FDA approval of our advanced, cost-effective

SSi Mantra surgical robotic system, Sarah brings strong financial leadership, keen strategic vision, and extensive capital markets experience.

She will play an integral role in scaling and enhancing our financial operations to accommodate our anticipated growth.”

Ms. Romano added, “I am delighted for this

opportunity to collaborate closely with Dr. Sudhir and the leadership team as SS Innovations delivers on its mission to democratize global

access to cutting-edge surgical robotic care.”

Ms. Romano is a seasoned public company finance

executive, bringing more than two decades of experience leading capital strategy, corporate growth, and financial operations in the medical

technology and life sciences industries. Most recently, Ms. Romano served as Chief Financial Officer of Vicarious Surgical, a robotic

surgery company where she led financial and operational initiatives to significantly reduce cash burn, strengthen the balance sheet, and

support the company’s strategic objectives. Previously, she served as Chief Financial Officer of Entero Therapeutics and Kiora Pharmaceuticals,

where she led capital raising activities, strategic transactions, SEC reporting, and investor relations programs. Throughout her career,

Ms. Romano has raised more than $100 million through public and private financings and has extensive experience supporting emerging growth

public companies, including robotic surgery and medical technology organizations, through periods of transformation, growth, and strategic

change.

Ms. Romano began her career as an auditor at PricewaterhouseCoopers

and is a licensed Certified Public Accountant (CPA) in Massachusetts. She earned a Bachelor of Arts in Accounting from the College of

the Holy Cross and Master of Accountancy in Accounting from Boston College.

About SS Innovations

SS Innovations International, Inc. (Nasdaq: SSII)

develops innovative surgical robotic technologies with a vision to make the benefits of robotic surgery affordable and accessible to a

larger segment of the global population. The Company’s product range includes its proprietary “SSi Mantra” surgical

robotic system and its comprehensive suite of “SSi Mudra” surgical instruments, which support a variety of surgical robotic

procedures including cardiac surgery. An American company headquartered in India, SS Innovations plans to expand the global presence of

its technologically advanced, user-friendly, and cost-effective surgical robotic solutions. Visit the Company’s website at ssinnovations.com

or LinkedIn for more information and updates.

About the SSi Mantra

The SSi Mantra is a user-friendly, modular, multi-arm

system with advanced technology features, including: 3 to 5 modular robotic arms, an open-faced ergonomic surgeon command center, a large

3D 4K monitor, a touch panel monitor for all patient-related information display, a virtual real-time image of the robotic patient side

arm carts, and the ability for superimposition of 3D models of diagnostic imaging. The optional SSi MantrAsana tele-surgeon console is

a portable, compact alternative to the SSi Mantra’s standard surgeon command center that provides equivalent control functionality

while enabling enhanced portability, ergonomic flexibility, and telesurgery capability. The SSi Mantra utilizes over 40 different types

of robotic endo-surgical instruments to support different specialties, including cardiac surgery, and 5mm instruments for the pediatric

population and ENT surgeries. A vision cart provides the table-side team with the same magnified 3D 4K view as the surgeon to provide

better safety and efficiency. The SSi Mantra has been clinically validated in India in more than 170 different types of surgical procedures.

Forward Looking Statements

This press release may contain statements that

are not historical facts and are considered forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995.

The words “anticipate,” “assume,” “believe,” “estimate,” “expect,” “will,”

“intend,” “may,” “plan,” “project,” “should,” “could,” “seek,”

“designed,” “potential,” “forecast,” “target,” “objective,” “goal,”

or the negatives of such terms or other similar expressions to identify such forward-looking statements. These statements relate to future

events or SS Innovations’ future financial performance and involve known and unknown risks, uncertainties and other factors that

may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels

of activity, performance or achievements expressed or implied by these forward-looking statements.

Investor Contact:

The Equity Group

Kalle Ahl, CFA

T: (303) 953-9878

kahl@theequitygroup.com

Devin Sullivan, Managing Director

T: (212) 836-9608

dsullivan@theequitygroup.com

Media Contact:

RooneyPartners LLC

Kate Barrette

T: (212) 223-0561

kbarrette@rooneypartners.com

GRAPHIC

GRAPHIC

Filename: ea029760101_ex99-1img1.jpg · Sequence: 4

Binary file (4637 bytes)

Download ea029760101_ex99-1img1.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 9

v3.26.1

Cover

Jul. 14, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Jul. 14, 2026

Entity File Number

001-42615

Entity Registrant Name

SS INNOVATIONS INTERNATIONAL, INC.

Entity Central Index Key

0001676163

Entity Tax Identification Number

47-3478854

Entity Incorporation, State or Country Code

FL

Entity Address, Address Line One

405, 3rd Floor

Entity Address, Address Line Two

iLabs Info Technology Centre

Entity Address, Address Line Three

Udyog Vihar, Phase III

Entity Address, City or Town

Gurugram

Entity Address, Country

IN

Entity Address, Postal Zip Code

122016

City Area Code

+91

Local Phone Number

73375 53469

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock

Trading Symbol

SSII

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

X

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

na

Period Type:

duration

X

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Address Line 3 such as an Office Park

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine3

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

ISO 3166-1 alpha-2 country code.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCountry

Namespace Prefix:

dei_

Data Type:

dei:countryCodeItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

na

Period Type:

duration

X

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration